apl. Prof. Dr. Sabine Semrau

Medizinische Fakultät

High Detection Accuracy of an optimized 3D Convolutional Neural Network for Auto Detection and Auto Segmentation of Brain Metastases (2021) Putz F, Weissmann T, Mansoorian S, Schmitter C, Semrau S, Lettmaier S, Masitho S, et al. Conference contribution 12 x 6 Gy stereotactic radiotherapy for lung tumours. Is there a difference in response between lung metastases and primary bronchial carcinoma? (2021) Lubgan D, Semrau S, Lambrecht U, Gaipl U, Fietkau R Conference contribution Prospective Assessment of the Inflammation Parameters in Blood Counts and Blood Serum as prognostic/predictive Parameters for Treatment with Immune Checkpoint-Inhibitors (2021) Schweizer C, Haderlein M, Schubert P, Zhou J, Semrau S, Rutzner S, Gostian AO, et al. Conference contribution Reirradiation of recurent glioblastomas: High prognostic significance of contrast-enhancing tumor volume (2021) Mansoorian S, Coras R, Weissmann T, Lettmaier S, Semrau S, Frey B, Bert C, et al. Conference contribution Longitudinal Spread Analysis of Patients with Glioblastoma: high Prevalence of discontinuous Tumor Foci with no strong Relation to the Fibrous Tract System (2021) Schmitter C, Weissmann T, Mansoorian S, Lettmaier S, Semrau S, Schmidt M, Heiß R, et al. Conference contribution 3D convolutional neural network-based autosegmentation improves brain metastases detection and quantification for brain stereotactic radiotherapy treatment planning (2021) Putz F, Weissmann T, Mansoorian S, Schmidt M, Heiß R, Semrau S, Frey B, et al. Conference contribution Radiotherapy for the elderly Patient with Head and Neck Squamous Cell Carcinoma - Experience of a Center for ENT-Tumors (2021) Winkler LS, Lettmaier S, Semrau S, Müller SK, Traxdorf M, Iro H, Kesting MR, et al. Conference contribution Progress Patterns under Radioimmunotherapy - clinical Evaluation of the prospective STICI Study (2021) Schubert P, Schweizer C, Roesch J, Haderlein M, Rutzner S, Semrau S, Donaubauer AJ, et al. Conference contribution Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+T-cell infiltration. (2021) Hecht M, Eckstein M, Rutzner S, von der Grün J, Illmer T, Klautke G, Laban S, et al. Conference contribution Implementation of double immune checkpoint blockade increases response rate to induction chemotherapy in head and neck cancer (2021) Semrau S, Gostian AO, Traxdorf M, Eckstein M, Rutzner S, von der Grün J, Illmer T, et al. Journal article